

# Ziyad Al-Aly

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3640754/publications.pdf>

Version: 2024-02-01

135  
papers

90,618  
citations

15001

68  
h-index

14779

131  
g-index

143  
all docs

143  
docs citations

143  
times ranked

112040  
citing authors

#	ARTICLE	IF	CITATIONS
1	We Must all Join the Effort to Dismantle Environmental Racism. Journal of the American Society of Nephrology: JASN, 2022, 33, 12-14.	3.0	3
2	Long-term cardiovascular outcomes of COVID-19. Nature Medicine, 2022, 28, 583-590.	15.2	1,029
3	Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019. JAMA Oncology, 2022, 8, 420.	3.4	719
4	Fine particulate matter components and interstitial lung disease in rheumatoid arthritis. European Respiratory Journal, 2022, 60, 2102149.	3.1	17
5	Risks of mental health outcomes in people with covid-19: cohort study. BMJ, The, 2022, 376, e068993.	3.0	199
6	Mental health in people with covid-19. BMJ, The, 2022, 376, o415.	3.0	3
7	Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diabetes and Endocrinology,the, 2022, 10, 311-321.	5.5	289
8	Measuring the availability of human resources for health and its relationship to universal health coverage for 204 countries and territories from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2022, 399, 2129-2154.	6.3	91
9	Long COVID after breakthrough SARS-CoV-2 infection. Nature Medicine, 2022, 28, 1461-1467.	15.2	460
10	Burden of diabetes and hyperglycaemia in adults in the Americas, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Diabetes and Endocrinology,the, 2022, 10, 655-667.	5.5	43
11	Acute Kidney Injury in a National Cohort of Hospitalized US Veterans with COVID-19. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 14-25.	2.2	158
12	Sustainable Development Goals relevant to kidney health: an update on progress. Nature Reviews Nephrology, 2021, 17, 15-32.	4.1	95
13	Temporal Trends in Incidence Rates of Lower Extremity Amputation and Associated Risk Factors Among Patients Using Veterans Health Administration Services From 2008 to 2018. JAMA Network Open, 2021, 4, e2033953.	2.8	53
14	The Road Ahead for Research on Air Pollution and Kidney Disease. Journal of the American Society of Nephrology: JASN, 2021, 32, 260-262.	3.0	8
15	County-Level Contextual Characteristics and Disparities in Life Expectancy. Mayo Clinic Proceedings, 2021, 96, 92-104.	1.4	11
16	Ambient Fine Particulate Matter Air Pollution and Risk of Weight Gain and Obesity in United States Veterans: An Observational Cohort Study. Environmental Health Perspectives, 2021, 129, 47003.	2.8	32
17	High-dimensional characterization of post-acute sequelae of COVID-19. Nature, 2021, 594, 259-264.	13.7	961
18	Spatial, temporal, and demographic patterns in prevalence of chewing tobacco use in 204 countries and territories, 1990â€“2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet Public Health, The, 2021, 6, e482-e499.	4.7	38

#	ARTICLE	IF	CITATIONS
19	Clinical Implications of Estimated Glomerular Filtration Rate Dip Following Sodium-Glucose Cotransporter-2 Inhibitor Initiation on Cardiovascular and Kidney Outcomes. <i>Journal of the American Heart Association</i> , 2021, 10, e020237.	1.6	19
20	Subnational mapping of HIV incidence and mortality among individuals aged 15-49 years in sub-Saharan Africa, 2000-18: a modelling study. <i>Lancet HIV</i> , 2021, 8, e363-e375.	2.1	32
21	Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019. <i>Lancet</i> , 2021, 397, 2337-2360.	6.3	609
22	Predicting the environmental suitability for onchocerciasis in Africa as an aid to elimination planning. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0008824.	1.3	10
23	Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes. <i>JAMA Internal Medicine</i> , 2021, 181, 1043.	2.6	32
24	Temporal trends of COVID-19 mortality and hospitalisation rates: an observational cohort study from the US Department of Veterans Affairs. <i>BMJ Open</i> , 2021, 11, e047369.	0.8	29
25	Kidney Outcomes in Long COVID. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2851-2862.	3.0	200
26	Global, regional, and national progress towards Sustainable Development Goal 3.2 for neonatal and child health: all-cause and cause-specific mortality findings from the Global Burden of Disease Study 2019. <i>Lancet</i> , 2021, 398, 870-905.	6.3	229
27	Ambient fine particulate matter air pollution and the risk of hospitalization among COVID-19 positive individuals: Cohort study. <i>Environment International</i> , 2021, 154, 106564.	4.8	70
28	Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018. <i>Nature Medicine</i> , 2021, 27, 1761-1782.	15.2	60
29	Association of Ambient Fine Particulate Matter Air Pollution With Kidney Transplant Outcomes. <i>JAMA Network Open</i> , 2021, 4, e2128190.	2.8	9
30	Global, regional, and national mortality among young people aged 10-24 years, 1950-2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet</i> , 2021, 398, 1593-1618.	6.3	92
31	Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes-Reply. <i>JAMA Internal Medicine</i> , 2021, , .	2.6	0
32	Burdens of post-acute sequelae of COVID-19 by severity of acute infection, demographics and health status. <i>Nature Communications</i> , 2021, 12, 6571.	5.8	196
33	Proton Pump Inhibitors and the Kidney: Implications of Current Evidence for Clinical Practice and When and How to Deprescribe. <i>American Journal of Kidney Diseases</i> , 2020, 75, 497-507.	2.1	86
34	Mapping disparities in education across low- and middle-income countries. <i>Nature</i> , 2020, 577, 235-238.	13.7	58
35	Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet</i> , 2020, 396, 1204-1222.	6.3	7,664
36	Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet</i> , 2020, 396, 1223-1249.	6.3	3,928

#	ARTICLE	IF	CITATIONS
37	Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950â€“2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1160-1203.	6.3	890
38	Mapping geographical inequalities in oral rehydration therapy coverage in low-income and middle-income countries, 2000â€“17. <i>The Lancet Global Health</i> , 2020, 8, e1038-e1060.	2.9	23
39	Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1250-1284.	6.3	330
40	Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases. <i>Diabetes Care</i> , 2020, 43, 2859-2869.	4.3	68
41	Comparative Effectiveness of the Sodiumâ€“Glucose Cotransporter 2 Inhibitor Empagliflozin Versus Other Antihyperglycemics on Risk of Major Adverse Kidney Events. <i>Diabetes Care</i> , 2020, 43, 2785-2795.	4.3	26
42	Mapping geographical inequalities in access to drinking water and sanitation facilities in low-income and middle-income countries, 2000â€“17. <i>The Lancet Global Health</i> , 2020, 8, e1162-e1185.	2.9	91
43	Comparative evaluation of clinical manifestations and risk of death in patients admitted to hospital with covid-19 and seasonal influenza: cohort study. <i>BMJ, The</i> , 2020, 371, m4677.	3.0	129
44	Air Pollution and Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 301-303.	2.2	27
45	Biomarkers of CKD in Children. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 894-896.	3.0	1
46	Diabetes Minimally Mediated the Association Between PM2.5 Air Pollution and Kidney Outcomes. <i>Scientific Reports</i> , 2020, 10, 4586.	1.6	21
47	Global, regional, and national burden of chronic kidney disease, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2020, 395, 709-733.	6.3	2,858
48	Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017. <i>Nature Medicine</i> , 2020, 26, 750-759.	15.2	47
49	The global and national burden of chronic kidney disease attributable to ambient fine particulate matter air pollution: a modelling study. <i>BMJ Global Health</i> , 2020, 5, e002063.	2.0	40
50	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017. <i>JAMA Oncology</i> , 2019, 5, 1749.	3.4	1,691
51	Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. <i>BMJ: British Medical Journal</i> , 2019, 365, l1580.	2.4	146
52	Estimates of the 2016 global burden of kidney disease attributable to ambient fine particulate matter air pollution. <i>BMJ Open</i> , 2019, 9, e022450.	0.8	58
53	Burden of Cause-Specific Mortality Associated With PM <sub>2.5</sub> Air Pollution in the United States. <i>JAMA Network Open</i> , 2019, 2, e1915834.	2.8	205
54	The State of US Health, 1990-2016. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1444.	3.8	1,042

#	ARTICLE	IF	CITATIONS
55	The association of proton pump inhibitors and chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2018, 27, 182-187.	1.0	16
56	Burden of obesity in the Eastern Mediterranean Region: findings from the Global Burden of Disease 2015 study. <i>International Journal of Public Health</i> , 2018, 63, 165-176.	1.0	50
57	Particulate Matter Air Pollution and the Risk of Incident CKD and Progression to ESRD. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 218-230.	3.0	225
58	Higher blood urea nitrogen is associated with increased risk of incident diabetes mellitus. <i>Kidney International</i> , 2018, 93, 741-752.	2.6	104
59	Diabetes mellitus and chronic kidney disease in the Eastern Mediterranean Region: findings from the Global Burden of Disease 2015 study. <i>International Journal of Public Health</i> , 2018, 63, 177-186.	1.0	30
60	Global, regional, and national age-sex-specific mortality and life expectancy, 1950â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1684-1735.	6.3	716
61	Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1736-1788.	6.3	4,989
62	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1923-1994.	6.3	3,269
63	Population and fertility by age and sex for 195 countries and territories, 1950â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1995-2051.	6.3	294
64	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1789-1858.	6.3	8,569
65	Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 2091-2138.	6.3	335
66	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1859-1922.	6.3	2,123
67	Changes in the US Burden of Chronic Kidney Disease From 2002 to 2016. <i>JAMA Network Open</i> , 2018, 1, e184412.	2.8	106
68	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2018, 391, 2236-2271.	6.3	638
69	The 2016 global and national burden of diabetes mellitus attributable to PM 2.5 air pollution. <i>Lancet Planetary Health</i> , The, 2018, 2, e301-e312.	5.1	240
70	Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. <i>Kidney International</i> , 2018, 94, 567-581.	2.6	592
71	Blood urea nitrogen and risk of insulin use among people with diabetes. <i>Diabetes and Vascular Disease Research</i> , 2018, 15, 409-416.	0.9	15
72	Alcohol use and burden for 195 countries and territories, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2018, 392, 1015-1035.	6.3	2,005

#	ARTICLE	IF	CITATIONS
73	Monocyte count modifies the association between chronic kidney disease and risk of death. <i>Clinical Nephrology</i> , 2018, 90, 194-208.	0.4	5
74	Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury. <i>Kidney International</i> , 2017, 91, 1482-1494.	2.6	134
75	Global Cardiovascular and Renal Outcomes of Reduced GFR. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2167-2179.	3.0	194
76	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2017, 390, 231-266.	6.3	480
77	Health Effects of Overweight and Obesity in 195 Countries over 25 Years. <i>New England Journal of Medicine</i> , 2017, 377, 13-27.	13.9	5,014
78	Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2017, 389, 1885-1906.	6.3	1,281
79	Association between Monocyte Count and Risk of Incident CKD and Progression to ESRD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 603-613.	2.2	56
80	Associations of ambient coarse particulate matter, nitrogen dioxide, and carbon monoxide with the risk of kidney disease: a cohort study. <i>Lancet Planetary Health, The</i> , 2017, 1, e267-e276.	5.1	131
81	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1084-1150.	6.3	573
82	Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1260-1344.	6.3	1,589
83	Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1151-1210.	6.3	3,565
84	Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1211-1259.	6.3	5,578
85	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1345-1422.	6.3	1,879
86	Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1423-1459.	6.3	284
87	Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans. <i>BMJ Open</i> , 2017, 7, e015735.	0.8	194
88	Geographic Variation and US County Characteristics Associated With Rapid Kidney Function Decline. <i>Kidney International Reports</i> , 2017, 2, 5-17.	0.4	42
89	Serum phosphorus levels and risk of incident dementia. <i>PLoS ONE</i> , 2017, 12, e0171377.	1.1	25
90	A big data approach to examine the association of high density lipoprotein cholesterol and mortality: lessons for future investigations. <i>Journal of Thoracic Disease</i> , 2017, 9, 4926-4928.	0.6	0

#	ARTICLE	IF	CITATIONS
91	High density lipoprotein cholesterol and risk of death. Journal of Thoracic Disease, 2016, 8, E1780-E1781.	0.6	2
92	Renal Function Trajectories in Patients with Prior Improved eGFR Slopes and Risk of Death. PLoS ONE, 2016, 11, e0149283.	1.1	29
93	Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD. Journal of the American Society of Nephrology: JASN, 2016, 27, 3153-3163.	3.0	263
94	Global, regional, and national levels of maternal mortality, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1775-1812.	6.3	740
95	Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1603-1658.	6.3	1,612
96	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1459-1544.	6.3	4,934
97	Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1545-1602.	6.3	5,298
98	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1659-1724.	6.3	4,203
99	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1813-1850.	6.3	413
100	High Density Lipoprotein Cholesterol and the Risk of All-Cause Mortality among U.S. Veterans. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1784-1793.	2.2	157
101	Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980â€“2015: the Global Burden of Disease Study 2015. Lancet HIV,the, 2016, 3, e361-e387.	2.1	461
102	Low levels of high-density lipoprotein cholesterol increase the risk of incident kidney disease and its progression. Kidney International, 2016, 89, 886-896.	2.6	101
103	Estimated GFR Trajectories of People Entering CKD Stage 4 and Subsequent Kidney Disease Outcomes and Mortality. American Journal of Kidney Diseases, 2016, 68, 219-228.	2.1	45
104	Acute kidney injury after cardiac surgery: is minocycline protective?. Journal of Nephrology, 2015, 28, 193-199.	0.9	8
105	Rate of Kidney Function Decline and Risk of Hospitalizations in Stage 3A CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1946-1955.	2.2	51
106	Prediction of renal end points in chronic kidney disease. Kidney International, 2013, 83, 189-191.	2.6	19
107	Mental health disorders and the risk of AIDS-defining illness and death in HIV-infected veterans. Aids, 2012, 26, 229-234.	1.0	51
108	Greater variability in kidney function is associated with an increased risk of death. Kidney International, 2012, 82, 1208-1214.	2.6	67

#	ARTICLE	IF	CITATIONS
109	Phosphate, oxidative stress, and nuclear factor- $\kappa$ B activation in vascular calcification. <i>Kidney International</i> , 2011, 79, 1044-1047.	2.6	44
110	Tumor necrosis factor- $\alpha$ blockade, cardiovascular outcomes, and survival in rheumatoid arthritis. <i>Translational Research</i> , 2011, 157, 10-18.	2.2	50
111	Early Nephrologist Involvement in Hospital-Acquired Acute Kidney Injury: A Pilot Study. <i>American Journal of Kidney Diseases</i> , 2011, 57, 228-234.	2.1	140
112	Rate of Change in Kidney Function and the Risk of Death: The Case for Incorporating the Rate of Kidney Function Decline into the CKD Staging System. <i>Nephron Clinical Practice</i> , 2011, 119, c179-c186.	2.3	8
113	Tamm-Horsfall protein-deficient thick ascending limbs promote injury to neighboring S3 segments in an MIP-2-dependent mechanism. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 300, F999-F1007.	1.3	72
114	Rate of Kidney Function Decline Associates with Mortality. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 1961-1969.	3.0	161
115	The new role of calcimimetics as vasculotropic agents. <i>Kidney International</i> , 2009, 75, 9-12.	2.6	8
116	Extracorporeal Management of Valproic Acid Toxicity: A Case Report and Review of the Literature. <i>Seminars in Dialysis</i> , 2008, 18, 62-66.	0.7	27
117	Renal allograft biopsies in the era of C4d staining: the need for change in the Banff classification system. <i>Transplant International</i> , 2008, 21, 268-275.	0.8	17
118	Arterial calcification: a tumor necrosis factor-alpha mediated vascular Wnt-opathy. <i>Translational Research</i> , 2008, 151, 233-239.	2.2	63
119	Vascular Calcification in Uremia: What Is New and Where Are We Going?. <i>Advances in Chronic Kidney Disease</i> , 2008, 15, 413-419.	0.6	23
120	Metabolic acidosis and vascular calcification: Using blueprints from bone to map a new venue for vascular research. <i>Kidney International</i> , 2008, 73, 377-379.	2.6	9
121	Vitamin D as a novel nontraditional risk factor for mortality in hemodialysis patients: The need for randomized trials. <i>Kidney International</i> , 2007, 72, 909-911.	2.6	19
122	Aortic <i>Msx2-Wnt</i> Calcification Cascade Is Regulated by TNF- $\alpha$ -Dependent Signals in Diabetic <i>Ldlr</i> Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 2589-2596.	1.1	279
123	INFLIXIMAB REDUCES AORTIC BMP2-MSX2-WNT SIGNALS AND VASCULAR CALCIFICATION IN DIABETIC LDLR MICE.. <i>Journal of Investigative Medicine</i> , 2007, 55, S350-S351.	0.7	0
124	Medial Vascular Calcification in Diabetes Mellitus and Chronic Kidney Disease: The Role of Inflammation. <i>Cardiovascular &amp; Hematological Disorders Drug Targets</i> , 2007, 7, 1-6.	0.2	43
125	Changes in Serum 25-Hydroxyvitamin D and Plasma Intact PTH Levels Following Treatment With Ergocalciferol in Patients With CKD. <i>American Journal of Kidney Diseases</i> , 2007, 50, 59-68.	2.1	147
126	Vascular <i>Bmp</i> <i>Msx2</i> <i>Wnt</i> Signaling and Oxidative Stress in Arterial Calcification. <i>Annals of the New York Academy of Sciences</i> , 2007, 1117, 40-50.	1.8	118



#	ARTICLE	IF	CITATIONS
127	Preliminary experience with mycophenolate mofetil for preservation of renal function in cardiac transplant patients with documented cyclosporine nephrotoxicity. <i>Nephrology</i> , 2006, 11, 151-155.	0.7	9
128	Assessment of Bone and Joint Diseases: Renal Osteodystrophy. , 2006, , 755-765.		0
129	Difficulties in Achieving the K/DOQI Practice Guidelines for Bone and Mineral Metabolism. <i>Seminars in Dialysis</i> , 2005, 18, 171-174.	0.7	11
130	The natural history of renal function following orthotopic heart transplant. <i>Clinical Transplantation</i> , 2005, 19, 683-689.	0.8	87
131	C4d peritubular capillary staining in chronic allograft nephropathy and transplant glomerulopathy: an uncommon finding. <i>Transplant International</i> , 2005, 18, 800-805.	0.8	27
132	Thrombotic thrombocytopenic purpura in a patient treated with imatinib mesylate: True association or mere coincidence?. <i>American Journal of Kidney Diseases</i> , 2005, 45, 762-768.	2.1	36
133	Achieving K/DOQI Laboratory Target Values for Bone and Mineral Metabolism: An Uphill Battle. <i>American Journal of Nephrology</i> , 2004, 24, 422-426.	1.4	63
134	Vascular biology in uremia: insights into novel mechanisms of vascular injury. <i>Advances in Chronic Kidney Disease</i> , 2004, 11, 310-318.	0.6	26
135	Routine Replacement of Tunneled, Cuffed, Hemodialysis Catheters Eliminates Paraspinal/Vertebral Infections in Patients with Catheter-Associated Bacteremia. <i>American Journal of Nephrology</i> , 2003, 23, 202-207.	1.4	42